Harbour Antibodies is a technology company.
Harbour Antibodies has raised $3.0M across 1 funding round.
Key people at Harbour Antibodies.
Harbour Antibodies has raised $3.0M in total across 1 funding round.
Key people at Harbour Antibodies.
Harbour Antibodies is a biotechnology company specializing in transgenic mouse platforms for discovering fully human monoclonal antibodies in H2L2 (two heavy and two light chain) and HCAb (heavy chain only) formats.[1][2][3][6] Acquired by Harbour BioMed in 2018, it now operates as a core technology pillar under Harbour BioMed (HKEX: 02142), a global biopharmaceutical firm focused on immunology and oncology therapeutics, serving biotech and pharma partners through licensing and collaborations to accelerate antibody drug development.[1][3][5] The company solves key challenges in antibody discovery by producing high-affinity, fully human antibodies without needing humanization or extra affinity maturation, reducing time and costs for next-generation therapies like bispecifics and immune cell engagers.[2][3][6]
Its growth momentum stems from integration into Harbour BioMed's ecosystem, with platforms like Harbour Mice® and HBICE® powering a robust pipeline and open-access model via Nona Biosciences, enabling widespread industry adoption.[1][3]
Harbour Antibodies BV was founded in 2006 in Rotterdam, Netherlands, by researchers from Erasmus Medical Center, including scientific founder Prof. Frank Grosveld, to commercialize his lab's transgenic mouse technology for generating high-affinity human antibodies.[2][3] Dr. Roger Craig is also noted as a founder.[3] The idea emerged from Grosveld's work engineering mice to produce "conventional" H2L2 antibodies and innovative HCAb formats, which enable soluble VH domains for multifunctional therapeutics.[2]
In 2018, Harbour BioMed—established in 2016 with $50M from investors like Advantech Capital and Legend Capital—acquired Harbour Antibodies, creating a global entity with R&D in Shanghai, Rotterdam, and Cambridge, MA (expanding to Boston).[1][3][5] This pivotal acquisition marked early traction, blending Dutch innovation with Asian manufacturing and U.S. business ops.[3]
Harbour Antibodies rides the next-generation antibody therapeutics wave, particularly in oncology and immunology, where demand surges for fully human, multispecific antibodies amid rising cancer prevalence and immunotherapy advances.[1][3] Timing aligns with post-2020 biopharma shifts toward efficient discovery platforms amid patent cliffs on blockbusters like Humira, favoring tech like HCAb for differentiated molecules unachievable by traditional methods.[1][2]
Market forces include booming bispecific/CD3 engager demand (projected multi-billion market) and China's biopharma rise via firms like Harbour BioMed.[1][3] It influences the ecosystem by licensing to global players, accelerating innovation—e.g., enabling smaller biotechs to compete—and powering Harbour BioMed's pipeline of clinical assets.[1][6]
Harbour Antibodies' platforms position it for expansion in AI-augmented discovery and ADCs/cell therapies, with Nona Biosciences scaling partnerships amid 2025's M&A surge in biotech.[1][3] Trends like precision oncology and autoimmune breakthroughs will amplify HCAb/HBICE® adoption, potentially driving Harbour BioMed's pipeline toward multiple INDs and approvals. Its influence may evolve from platform licensor to key enabler in a consolidated biopharma landscape, sustaining momentum from that 2006 Dutch lab spark into global therapeutic impact.[1][2][3]
Harbour Antibodies has raised $3.0M in total across 1 funding round.
Harbour Antibodies's investors include Atlas Venture.
Harbour Antibodies has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in July 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2013 | $3.0M Series A | Atlas Venture |
